Interleukin‐29 profiles in COVID‐19 patients: Survival is associated with IL‐29 levels

Student Research committee, Department of Laboratory Sciences, Faculty of Allied Medical Sciences, Ilam University of Medical Sciences, Ilam, Iran Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran Department of Physiology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran Immunogenetics Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran Department of Immunology, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran Zoonotic Diseases Research Center, Ilam University of Medical Science, Ilam, Iran Student Research Committee, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran Department of Physiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran Department of Clinical Immunology, Ilam University of Medical Science, Ilam, Iran Department of Physiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran Department of Microbiology, Faculty of Medicine, Ilam University of Medical Science, Ilam, Iran Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran Department of Laboratory and Clinical Science, Faculty of Veterinary Medicine, Ilam University, Ilam, Iran

[1]  Yuetian Yu,et al.  Identification of risk factors for mortality associated with COVID-19 , 2020, PeerJ.

[2]  M. Merad,et al.  Immunology of COVID-19: Current State of the Science , 2020, Immunity.

[3]  C. Hedrich,et al.  COVID-19: Immunology and treatment options , 2020, Clinical Immunology.

[4]  L. Prokunina-Olsson,et al.  Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019 , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[5]  L. Prokunina-Olsson,et al.  Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Zhongheng Zhang,et al.  Clinical characteristics of Coronavirus Disease 2019 and development of a prediction model for prolonged hospital length of stay , 2020, Annals of translational medicine.

[7]  B. Medhi,et al.  Drug targets for corona virus: A systematic review , 2020, Indian journal of pharmacology.

[8]  L. Su,et al.  Insights into IL‐29: Emerging role in inflammatory autoimmune diseases , 2019, Journal of cellular and molecular medicine.

[9]  M. Diamond,et al.  Shared and Distinct Functions of Type I and Type III Interferons. , 2019, Immunity.

[10]  S. Kotenko,et al.  Interferon‐&lgr; Mediates Non‐redundant Front‐Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness , 2017, Immunity.

[11]  Yujiang Fang,et al.  The role of IL-29 in immunity and cancer , 2016, Critical Reviews in Oncology/Hematology.

[12]  S. Paludan,et al.  Interferon-λ Is Functionally an Interferon but Structurally Related to the Interleukin-10 Family* , 2009, The Journal of Biological Chemistry.

[13]  F. Mennechet,et al.  Interferon-λ-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells , 2006 .